Clinical Trials: Available

Disclaimer: Information regarding clinical trials for NPC disease is obtained from the website and may not capture every trial. Please see links for additional information about specific clinical trials.

Early Access Program With Arimoclomol in US Patients With NPC ID
Last Update Posted
November 14, 2023
Information provided by
ZevraDenmark (Responsible Party)
Study Description:

The purpose of this Expanded Access Program is to provide early access to arimoclomol for patients with Niemann-Pick Type C disease who, in the opinion and the clinical judgement of the treating physician, may benefit from treatment with arimoclomol.

More information can be found on

Share This Content